Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 17, 12, 19, 12, 23.
New guidelines and consensus this year
All papers from the last 12 months
511 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis modelsMatrix Biol Plus2026 DecPMID 42730024
- Spatial distribution of fibroblastic foci in transbronchial lung cryobiopsy specimensAnn Diagn Pathol2026 DecPMID 42636713
- Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)Ann Med2026 DecPMID 41852279
- Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axisJ Ethnopharmacol2026 Nov 15PMID 42302945
- Targeting the Snail1-ATGL-ferroptosis-EMT axis via AKT-GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosisEur J Pharmacol2026 Nov 10PMID 42785459
- Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung diseaseCurr Opin Rheumatol2026 Nov 1PMID 42712119Review
- Inhalation therapies in interstitial lung diseasesExpert Opin Drug Deliv2026 Oct 15PMID 42858239Review
- Structure based identification of novel 4,5,6,7-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one derivatives as nonacidic ATX inhibitors with promising antifibrotic effectsEur J Med Chem2026 Oct 15PMID 42224938
- Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: immunomodulation and antifibrotic therapy as complementary strategies?Respir Med2026 Oct 14PMID 42874937
- Interstitial lung disease as the initial manifestation of systemic autoimmune disease: a narrative review of autoantibodies, biomarkers, prognosis, and managementClin Exp Rheumatol2026 Oct 13PMID 42873695Review
More pulmonology trends
All specialties →Biologics in COPD
Dupilumab and other biologics for COPD with type 2 inflammation.
Key point: Pooled analyses suggest dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD.
Bronchiectasis
Non-cystic fibrosis bronchiectasis and its newer treatments.
Robotic and navigational bronchoscopy
Robotic and navigation bronchoscopy to biopsy peripheral lung nodules.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Lung cancer screening
Low-dose CT screening for lung cancer.
Key point: Low-dose CT screening reduces lung cancer death risk by at least 21% and should be offered to people aged 50–75 with at least 20 pack-years.
E-cigarettes and the lungs
Respiratory effects of vaping and e-cigarettes.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("progressive pulmonary fibrosis"[tiab] OR "idiopathic pulmonary fibrosis"[tiab]) AND (nintedanib[tiab] OR pirfenidone[tiab] OR nerandomilast[tiab] OR antifibrotic*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.